AMPHETAMINE SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Amphetamine Sulfate patents expire, and when can generic versions of Amphetamine Sulfate launch?
Amphetamine Sulfate is a drug marketed by Alkem Labs Ltd, Amneal Pharms, Aurolife Pharma Llc, Bionpharma, Dr Reddys Labs Sa, Epic Pharma Llc, Glenmark Pharms Ltd, Granules, Lannett, Novast Labs, Prinston Inc, Rhodes Pharms, Sanaluz, Senores Pharms, Specgx Llc, and Sun Pharm Inds Inc. and is included in sixteen NDAs.
The generic ingredient in AMPHETAMINE SULFATE is amphetamine sulfate. There are fifty-five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amphetamine Sulfate
A generic version of AMPHETAMINE SULFATE was approved as amphetamine sulfate by AMNEAL PHARMS on September 26th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMPHETAMINE SULFATE?
- What are the global sales for AMPHETAMINE SULFATE?
- What is Average Wholesale Price for AMPHETAMINE SULFATE?
Summary for AMPHETAMINE SULFATE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 16 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 24 |
| Clinical Trials: | 8 |
| Patent Applications: | 984 |
| Drug Prices: | Drug price information for AMPHETAMINE SULFATE |
| DailyMed Link: | AMPHETAMINE SULFATE at DailyMed |
Recent Clinical Trials for AMPHETAMINE SULFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vallon Pharmaceuticals, Inc. | Phase 1 |
| Arbor Pharmaceuticals, Inc. | Phase 3 |
| Sarah Morrow | Phase 2/Phase 3 |
Pharmacology for AMPHETAMINE SULFATE
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for AMPHETAMINE SULFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | AMPHETAMINE SULFATE | amphetamine sulfate | TABLET;ORAL | 214574-002 | Jan 27, 2021 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Senores Pharms | AMPHETAMINE SULFATE | amphetamine sulfate | TABLET;ORAL | 212901-002 | May 22, 2020 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Specgx Llc | AMPHETAMINE SULFATE | amphetamine sulfate | TABLET;ORAL | 213583-001 | Jan 22, 2021 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
